{"entity":{"id":"nct07294508","kind":"trial","name":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","aka":[],"tldr":"A phase 2/3 trial of Pertuzumab in HER2-positive breast cancer, run by Shanghai Henlius Biotech, now recruiting.","summary":"A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer is a phase 2/3 interventional study registered as NCT07294508 by Shanghai Henlius Biotech, with 706 participants planned, started 2026-02-27 and due to reach its primary completion in 2028-01-15. Interventions recorded: HLX87 + HLX22, HLX87 + Pertuzumab, T-Dxd + Pertuzumab and THP.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07294508","url":"https://clinicaltrials.gov/study/NCT07294508"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":["pertuzumab"],"companies":["henlius"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07294508","phase":"2/3","setting":"An Open-Label, Randomized, Multicenter, Phase II/III Clinical Study to Evaluate HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With HLX87 (HER2 ADC) as First-Line Treatment in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer","sponsor":"Shanghai Henlius Biotech","enrolled":706,"outcomes":[]},"route":"/trials/nct07294508/","neighbours":{"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"pertuzumab","kind":"drug","name":"Pertuzumab","route":"/drugs/pertuzumab/"}],"company":[{"id":"henlius","kind":"company","name":"Shanghai Henlius Biotech","route":"/companies/henlius/"}]}}